PHARMACY

ANI gains 7 products from Amneal-Impax merger
The company said that the market for the seven products sits at roughly $1.7 billion annually, according to IQVIA data.
Upsher-Smith intros generic Cardura
The product had a U.S. market size of roughly $51.2 million for the 12 months ended January 2018, according to IQVIA data.

AAM adds board member, other members

The Association for Accessible Medicines has new regular and associate members, as well as a new addition to its board of directors.
Camber launches generic Methylin

The drug is indicated to treat attention deficit hyperactivity disorder.
Diplomat launches specialty benefit manager CastiaRx

The company said that CastiaRx is designed to help improve patient adherence and outcomes while managing specialty costs, which the IQVIA Institute for Human Data Science recently projected would make up more than 50% of U.S. drug spend by 2020.
FTC clears Amneal, Impax merger

ANI Pharmaceuticals, G&W Labs and Perrigo will acquire certain products that the companies have to divest ahead of their merger closing.
Fred’s CEO Bloom departs

Fred’s said Bloom’s departure, which included his resignation from the board of directors, was to pursue other opportunities and not due to a disagreement with the company or its operations.
CVS Health touts opioid disposal results

Ahead of Saturday’s National Prescription Drug Take-Back Day, CVS Health said that its disposal efforts had collected almost 350,000 pounds of unwanted medication since their inception.
AllianceRx Walgreens Prime gains access to 4 new specialty drugs

The four drugs now available for AllianceRx Walgreens Prime and Walgreens patients include Austedo (deutetrabenazine), Fasenra (benralizumab), Hemlibra (emicizumab-kxwh) and Symdeko (tezacaftor/ivacaftor and ivacaftor).
AmerisourceBergen Foundation launches Opioid Resource Grant Program

To oversee the grantmaking process, the foundation said it created an External Advisory Committee whose members include key stakeholders and thought leaders.